- Home
- MPW vs MRUS Comparison
MPW vs MRUS Comparison
Compare MPW & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- MRUS
- Stock Information
- Founded
- MPW 2003
- MRUS 2003
- Country
- MPW United States
- MRUS Netherlands
- Employees
- MPW N/A
- MRUS 260
- Industry
- MPW Real Estate Investment Trusts
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- MRUS Health Care
- Exchange
- MPW Nasdaq
- MRUS Nasdaq
- Market Cap
- MPW 3.0B
- MRUS 4.1B
- IPO Year
- MPW 2005
- MRUS 2016
- Fundamental
- Price
- MPW $4.44
- MRUS $53.11
- Analyst Decision
- MPW Hold
- MRUS Strong Buy
- Analyst Count
- MPW 6
- MRUS 12
- Target Price
- MPW $5.75
- MRUS $87.92
- AVG Volume (30 Days)
- MPW 7.9M
- MRUS 2.0M
- Earning Date
- MPW 08-07-2025
- MRUS 07-31-2025
- Dividend Yield
- MPW 7.19%
- MRUS N/A
- EPS Growth
- MPW N/A
- MRUS N/A
- EPS
- MPW N/A
- MRUS N/A
- Revenue
- MPW $994,715,000.00
- MRUS $54,732,000.00
- Revenue This Year
- MPW N/A
- MRUS $75.57
- Revenue Next Year
- MPW $7.11
- MRUS $31.84
- P/E Ratio
- MPW N/A
- MRUS N/A
- Revenue Growth
- MPW 23.40
- MRUS 42.77
- 52 Week Low
- MPW $3.51
- MRUS $33.19
- 52 Week High
- MPW $6.55
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- MPW 36.92
- MRUS 53.18
- Support Level
- MPW $4.35
- MRUS $52.41
- Resistance Level
- MPW $4.55
- MRUS $54.59
- Average True Range (ATR)
- MPW 0.14
- MRUS 2.15
- MACD
- MPW 0.02
- MRUS -0.77
- Stochastic Oscillator
- MPW 25.76
- MRUS 7.62
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.